Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

about

Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.

P2860

Q38927295-E22350E9-DDD7-41AA-BA4B-F6A0DD03731E

P2860

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

Item

http://www.wikidata.org/entity/Q36597950

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

@ast

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

@en

type

Item

label

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

@ast

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

@en

prefLabel

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

@ast

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

@en

P1476

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

@en

P2093

Fahed Al Darazi

http://www.w3.org/2001/XMLSchema#string

Karl T Weber

http://www.w3.org/2001/XMLSchema#string

Kevin P Newman

http://www.w3.org/2001/XMLSchema#string

Kodangudi B Ramanathan

http://www.w3.org/2001/XMLSchema#string

Michael R Seawell

http://www.w3.org/2001/XMLSchema#string

Syamal K Bhattacharya

http://www.w3.org/2001/XMLSchema#string

Victor Farah

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence for alteration of the vitamin D-endocrine system in blacks

The danger model: a renewed sense of self

Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Cardiac Abnormalities in Patients with Primary Hyperparathyroidism: Implications for Follow-Up

Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism.

Cardiac structure and diastolic function in mild primary hyperparathyroidism.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Structural basis of end-stage failure in ischemic cardiomyopathy in humans.

Hypokalemia and sudden cardiac death.

P2888

s11897-012-0120-x

P304

36-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11897-012-0120-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232745369

http://www.w3.org/2001/XMLSchema#string

P698

23114591

http://www.w3.org/2001/XMLSchema#string

P932

3568253

http://www.w3.org/2001/XMLSchema#string

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

about

P2860

P2860

Mineralocorticoid receptor antagonism confers cardioprotection in heart failure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P932